FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 616 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... October 16, 2024 Disease in a dish: Mini-gut organoids and the challenges of bowel... February 11, 2022 FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection February 7, 2025 A More Treatable Kind of Metastatic Cancer? October 5, 2020 Load more HOT NEWS Can I Have a Non-Violent Relationship with Cancer (Part 2) Husband Moved To Tears After Opening Christmas Gift From Wife Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors A Painful Breast Lump May Be Mistaken For Cancer When It’s...
